Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?

被引：1
|
作者：
Calvo Romero, J. M. [1 ]
机构：
[1] Hosp Ciudad Coria, Med Interna Serv, Coria, Caceres, Spain
来源：
REVISTA CLINICA ESPANOLA | 2011年 / 211卷 / 03期
关键词：
Dabigatran; Direct thrombin inhibitor; Vitamin K antagonist; Atrial fibrillation; INTERNATIONAL NORMALIZED RATIO; DIRECT THROMBIN INHIBITOR; ORAL ANTICOAGULATION; RISK STRATIFICATION; PREDICTING STROKE; GENERAL-PRACTICE; WARFARIN; THERAPY; MANAGEMENT; ETEXILATE;
D O I：
10.1016/j.rce.2010.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage. (C) 2011 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：142 / 146
页数：5
相关论文
共 50 条
  • [1] Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
    Chevalier, Julie
    Delaitre, Olivier
    Hammes, Florence
    de Pouvourville, Gerard
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2014, 107 (6-7) : 381 - 390
  • [2] Dabigatran for the prevention of stroke in patients with atrial fibrillation
    Diener, Hans-Christoph
    Weber, Ralph
    Weimar, Christian
    Frank, Benedikt
    Kirchhof, Paulus
    PSYCHOPHARMAKOTHERAPIE, 2011, 18 (04): : 156 - +
  • [3] Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists
    Barrios, Vivencio
    Escobar, Carlos
    Jose Gomez-Doblas, Juan
    Fernandez-Duenas, Jaime
    Romero Garrido, Rafael
    Pindado Rodriguez, Javier
    Umaran Sanchez, Juana
    Arellano-Rodrigo, Eduardo
    Donado, Esther
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (09) : 615 - 625
  • [4] Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease
    Strange, J. E.
    Sindet-Pedersen, C.
    Staerk, L.
    Grove, E. L.
    Gerds, T. A.
    Torp-Pedersen, C.
    Gislason, G. H.
    Butt, J. H.
    Fosboel, E. L.
    Olesen, J. B.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2996 - 2996
  • [5] Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
    Kozlowski, Dariusz
    Budrejko, Szymon
    Raczak, Grzegorz
    Rysz, Jacek
    Banach, Maciej
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (21) : 3816 - 3826
  • [6] Dabigatran for Stroke Prevention in All Patients with Atrial Fibrillation?
    Hunchuck, Jonathan E.
    Lake, Jennifer D.
    PHARMACOTHERAPY, 2011, 31 (08): : 725 - 728
  • [7] Dabigatran for stroke prevention in atrial fibrillation
    Hohnloser, S. H.
    Diener, H. -C.
    HAMOSTASEOLOGIE, 2012, 32 (03): : 216 - 220
  • [8] Patients' knowledge and perspectives on vitamin K antagonists for stroke prevention in atrial fibrillation: implications for treatment quality
    Polovina, Marija
    Djikic, Dijana
    Vlajkovic, Ana
    Vilotijevic, Matej
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 18 (03): : 239 - 240
  • [9] Vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) in very elderly naive patients
    Granziera, S.
    Bertozzo, G.
    Marigo, L.
    Petruzzellis, F.
    Rossi, K.
    Infante, T.
    Pletti, S.
    Nante, G.
    Manzato, E.
    Pengo, V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 559 - 559
  • [10] New oral anticoagulants are inferior to vitamin-K-antagonists for stroke prevention in elderly patients with atrial fibrillation
    Guenduez, D.
    Finsterer, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 : S28 - S28
12345